FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer By Ogkologos - August 26, 2026 14 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-B15/EV-304 study Source RELATED ARTICLESMORE FROM AUTHOR New Translations of the ESMO Patient Guides Available in Estonian Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and Trametinib Over Targeted Therapy Alone for BRAF V600-mutated Metastatic Melanoma Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer MOST POPULAR Precision drug slows progression of advanced breast cancer September 21, 2021 The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... September 20, 2021 Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal... January 23, 2023 FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML June 13, 2022 Load more HOT NEWS 7 Practical Tips for Taking Long-Term Medication In the Name of Pinkness Zanubrutinib’s Approval Improves Targeted Treatment for CLL Larger NGS Gene Panel Linked to More Clinical Utility
